Onco Wiki / drapeau rouge

Survivant du cancer ≥5 ans après la fin du traitement oncologique à intention curative qui comprend...

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

IDRF-IATROGENIC-ANTHRACYCLINE-LATE-CARDIO-PREVENTION
TypeSignal d’alerte
Étatreviewed 2026-05-18 | pending_clinical_signoff
MaladiesDIS-AML
SourcesSRC-COG SRC-NCCN-AML-2025 SRC-NCCN-BCELL-2025

Origine du drapeau rouge

DéfinitionCancer survivor ≥5 years post-completion of curative-intent oncology treatment that included cumulative anthracycline exposure ≥250 mg/m² (doxorubicin equivalent). Distinct from RF-IATROGENIC-ANTHRACYCLINE-CARDIO-PREVENTION (general anthracycline cardio surveillance starting at completion): this RF targets the long-term cancer-survivor cohort 5y+ post-treatment where surveillance cadence is set by Children's Oncology Group Long-Term Follow-Up Guidelines (COG-LTFU) + ASCO Cardio-Oncology Survivorship + ESC 2022 Cardio-Oncology. Late-effect cardiomyopathy incidence rises through decades post-exposure — childhood cancer survivors with cumulative doxorubicin ≥250 mg/m² have 5-15× HF risk vs. siblings at 30y of follow-up (Childhood Cancer Survivor Study). Risk amplifiers concurrent chest RT, age <18 or ≥65 at exposure, hypertension/diabetes/CAD. Prevention-persona RedFlag (§20 cancer-survivo...
Direction cliniqueenquêter
Catégorieautres

Logique de déclenchement

{
  "any_of": [
    {
      "finding": "survivor_5y_post_anthracycline_cumulative_ge_250_mg_m2",
      "value": true
    },
    {
      "finding": "survivor_anthracycline_plus_chest_rt_late_effect",
      "value": true
    },
    {
      "finding": "survivor_pediatric_anthracycline_late_effect",
      "value": true
    }
  ],
  "type": "lab_value"
}

Notes

Cancer-survivor late-effects RedFlag for cumulative anthracycline ≥250 mg/m² with ≥5y post-treatment interval. Distinct from RF-IATROGENIC-ANTHRACYCLINE-CARDIO-PREVENTION (general cardio surveillance starting at treatment completion). COG-LTFU-driven echo cadence q1-5y based on dose + chest RT + age at exposure. STUB pending two-Clinical-Co-Lead signoff per CHARTER §6.1 dev-mode.

Utilisé par

Indication